Doxorubicin vs CMF in the adjuvant treatment of high risk breast cancer

被引：0
|
作者：
Semiglazov, VF [1 ]
Bozhok, AA [1 ]
Ivanova, OA [1 ]
Iranov, VG [1 ]
Golubeva, OM [1 ]
机构：
[1] NN Petrov Oncol Res Inst, St Petersburg, Russia
来源：
EUROPEAN JOURNAL OF CANCER | 1998年 / 34卷
关键词：
D O I：
10.1016/S0959-8049(98)80154-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
167
引用
收藏
页码：S41 / S41
页数：1
相关论文
共 50 条
  • [31] DOXORUBICIN ADJUVANT COMBINATIONS FOR BREAST-CANCER
    SAUTER, C
    LANCET, 1993, 342 (8886-7): : 1550 - 1551
  • [32] CMF VS ALTERNATING CMF/EV IN THE ADJUVANT TREATMENT OF OPERABLE BREAST-CANCER - A SINGLE-CENTER RANDOMIZED CLINICAL-TRIAL (NAPLES GUN-3 STUDY)
    DEPLACIDO, S
    PERRONE, F
    CARLOMAGNO, C
    MORABITO, A
    PAGLIARULO, C
    LAURIA, R
    MARINELLI, A
    DELAURENTIIS, M
    VARRIALE, E
    PETRELLA, G
    GALLO, C
    BIANCO, AR
    BRITISH JOURNAL OF CANCER, 1995, 71 (06) : 1283 - 1287
  • [33] Cost of adjuvant chemotherapy (CT) with CMF and tamoxifen in breast cancer (BC)
    Abdyldaev, RA
    Abdyldaev, TA
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S15 - S15
  • [34] Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients
    Magne, Nicolas
    Castadot, Pierre
    Chargari, Cyrus
    Di Leo, Angelo
    Philippson, Catherine
    Van Houtte, Paul
    RADIOTHERAPY AND ONCOLOGY, 2009, 90 (01) : 116 - 121
  • [35] ADJUVANT CHEMOTHERAPY IN BREAST-CANCER - COMPARISON OF CMF AND NOSTE THERAPY
    HEISS, C
    MINK, D
    BRACK, T
    SCHMIDT, W
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1993, 254 (1-4) : 900 - 901
  • [36] PRESENT STATUS OF CMF ADJUVANT THERAPY IN OPERABLE BREAST-CANCER
    BONADONNA, G
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1977, 2 (3-4): : 237 - 240
  • [37] Pegylated liposomal doxorubicin for adjuvant treatment of breast cancer in patients refusing therapy with conventional doxorubicin.
    Manenfe, P.
    Vicario, G.
    Sgarbossa, G.
    Girardi, F.
    Bortolin, M.
    Scelzi, E.
    Sartor, L.
    Vultaggio, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Doxorubicin (A) followed by docetaxel (T) versus doxorubicin plus docetaxel (AT) in the adjuvant treatment of breast cancer (BC)
    Di Leo, A
    Crown, J
    Nogaret, LM
    Duffy, K
    Bartholomeus, S
    Dolci, S
    Rowan, S
    O'Higgins, N
    Riva, A
    Piccart, MJ
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S41 - S41
  • [39] Adjuvant treatment of breast cancer: A pilot immunochemotherapy study with CMF, interleukin-2 and interferon alpha
    Giuseppe Tonini
    Corrado Nunziata
    Salvatore P. Prete
    Rita Pepponi
    Mario Turriziani
    Giovanna Masci
    Grazia Graziani
    Enzo Bonmassar
    Liana De Vecchis
    Cancer Immunology, Immunotherapy, 1998, 47 : 157 - 166
  • [40] PHARMACOECONOMIC COMPARISON OF TWO PROTOCOLS FAC VS. CMF IN THE TREATMENT OF EARLY BREAST CANCER
    Ilic, M.
    Horvat, O.
    Sabo, A.
    Muzikravic, L.
    Jovanovic, D.
    Tomic, Z.
    VALUE IN HEALTH, 2008, 11 (06) : A470 - A471
12345